Logo image of HEXO

HEXO CORP (HEXO) Stock Fundamental Analysis

NASDAQ:HEXO - Nasdaq - CA4283044069 - Common Stock - Currency: USD

0.71  +0.02 (+2.45%)

After market: 0.69 -0.02 (-2.82%)

Fundamental Rating

1

Taking everything into account, HEXO scores 1 out of 10 in our fundamental rating. HEXO was compared to 195 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of HEXO have multiple concerns. HEXO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year HEXO has reported negative net income.
HEXO had a negative operating cash flow in the past year.
In the past 5 years HEXO always reported negative net income.
In the past 5 years HEXO always reported negative operating cash flow.
HEXO Yearly Net Income VS EBIT VS OCF VS FCFHEXO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -200M -400M -600M -800M -1B

1.2 Ratios

HEXO has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
HEXO Yearly ROA, ROE, ROICHEXO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 -100 -200 -300

1.3 Margins

HEXO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
HEXO Yearly Profit, Operating, Gross MarginsHEXO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -200 -400 -600

More info and screens

1

2. Health

2.1 Basic Checks

HEXO does not have a ROIC to compare to the WACC, probably because it is not profitable.
HEXO has more shares outstanding than it did 1 year ago.
The debt/assets ratio for HEXO has been reduced compared to a year ago.
HEXO Yearly Shares OutstandingHEXO Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M 100M
HEXO Yearly Total Debt VS Total AssetsHEXO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M 800M 1B

2.2 Solvency

HEXO has an Altman-Z score of -7.92. This is a bad value and indicates that HEXO is not financially healthy and even has some risk of bankruptcy.
HEXO has a Altman-Z score of -7.92. This is in the lower half of the industry: HEXO underperforms 70.64% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that HEXO is not too dependend on debt financing.
HEXO has a Debt to Equity ratio (0.01) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z -7.92
ROIC/WACCN/A
WACC3.02%
HEXO Yearly LT Debt VS Equity VS FCFHEXO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 200M -200M 400M 600M

2.3 Liquidity

A Current Ratio of 0.41 indicates that HEXO may have some problems paying its short term obligations.
With a Current ratio value of 0.41, HEXO is not doing good in the industry: 93.12% of the companies in the same industry are doing better.
HEXO has a Quick Ratio of 0.41. This is a bad value and indicates that HEXO is not financially healthy enough and could expect problems in meeting its short term obligations.
With a Quick ratio value of 0.24, HEXO is not doing good in the industry: 93.58% of the companies in the same industry are doing better.
Industry RankSector Rank
Current Ratio 0.41
Quick Ratio 0.24
HEXO Yearly Current Assets VS Current LiabilitesHEXO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 200M 400M 600M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 90.82% over the past year.
HEXO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -47.74%.
The Revenue has been growing by 115.62% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)90.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.6%
Revenue 1Y (TTM)-47.74%
Revenue growth 3Y59%
Revenue growth 5Y115.62%
Sales Q2Q%-52.63%

3.2 Future

HEXO is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 18.92% yearly.
Based on estimates for the next years, HEXO will show a decrease in Revenue. The Revenue will decrease by -5.44% on average per year.
EPS Next Y99.88%
EPS Next 2Y41.35%
EPS Next 3Y25.96%
EPS Next 5Y18.92%
Revenue Next Year-42.24%
Revenue Next 2Y-21.51%
Revenue Next 3Y-9.95%
Revenue Next 5Y-5.44%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
HEXO Yearly Revenue VS EstimatesHEXO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2030 100M 200M 300M 400M 500M
HEXO Yearly EPS VS EstimatesHEXO Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -200 -400 -600 -800

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for HEXO. In the last year negative earnings were reported.
Also next year HEXO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
HEXO Price Earnings VS Forward Price EarningsHEXO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 5 10 15 20 25

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
HEXO Per share dataHEXO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -10 -20 -30

4.3 Compensation for Growth

HEXO's earnings are expected to grow with 25.96% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.35%
EPS Next 3Y25.96%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for HEXO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

HEXO CORP

NASDAQ:HEXO (6/22/2023, 8:09:01 PM)

After market: 0.69 -0.02 (-2.82%)

0.71

+0.02 (+2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)06-14 2023-06-14/amc
Earnings (Next)10-31 2023-10-31/amc
Inst Owners2.75%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap30.80M
Analysts46.67
Price Target1.23 (73.24%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-3004.62%
Min EPS beat(2)-5995.95%
Max EPS beat(2)-13.29%
EPS beat(4)1
Avg EPS beat(4)-1525.55%
Min EPS beat(4)-5995.95%
Max EPS beat(4)97.53%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-25.3%
Min Revenue beat(2)-34.46%
Max Revenue beat(2)-16.13%
Revenue beat(4)0
Avg Revenue beat(4)-16.54%
Min Revenue beat(4)-34.46%
Max Revenue beat(4)-5.76%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-0.7%
PT rev (3m)-17.75%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)76.11%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-25.43%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.33
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)-30.52
EYN/A
EPS(NY)-0.54
Fwd EYN/A
FCF(TTM)-0.83
FCFYN/A
OCF(TTM)-0.67
OCFYN/A
SpS2.16
BVpS2.48
TBVpS1.26
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.31
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 32.53%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.41
Quick Ratio 0.24
Altman-Z -7.92
F-Score3
WACC3.02%
ROIC/WACCN/A
Cap/Depr(3y)357.42%
Cap/Depr(5y)1584.68%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)90.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%98.6%
EPS Next Y99.88%
EPS Next 2Y41.35%
EPS Next 3Y25.96%
EPS Next 5Y18.92%
Revenue 1Y (TTM)-47.74%
Revenue growth 3Y59%
Revenue growth 5Y115.62%
Sales Q2Q%-52.63%
Revenue Next Year-42.24%
Revenue Next 2Y-21.51%
Revenue Next 3Y-9.95%
Revenue Next 5Y-5.44%
EBIT growth 1Y54.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year99.56%
EBIT Next 3Y26.3%
EBIT Next 5Y19.3%
FCF growth 1Y-17.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-118.11%
OCF growth 3YN/A
OCF growth 5YN/A